Fourth, expression of activated BRAF V600E alone does not lead to tumor development in in vitro and in in vivo mouse models, while the combined activation of BRAF and loss of CDKN2A/B is transforming, suggesting that additional mutations to bypass senescence are required to advance to phase III [92, 182, 189]. Here, BRAF is linked to neoplasm.